In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

Some 20 weeks after stopping their drugs, the participants in the studies had put back on an average of 2.5 kilograms (5.5 ...

A recent study revealed that individuals taking weight-loss drugs, including renowned GLP-1s, may significantly regain weight ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.